Literature DB >> 2550616

Relation between density (maximum binding) of alpha adrenoceptor binding sites and contractile response in four canine vascular tissues.

A G Shi1, C Y Kwan, E E Daniel.   

Abstract

In microsomal fractions from dog aorta, saphenous veins, mesenteric arteries and veins, both [3H]prazosin and [3H]rauwolscine displayed monophasic saturation in binding. The Kd for [3H] rauwolscine binding was similar for all these blood vessels, but the maximum number of [3H]rauwolscine binding sites was 3 to 7 times higher in veins compared to arteries. The Kd for [3H] prazosin was higher in saphenous vein than that in the arteries. The maximum number of binding sites for [3H]prazosin was similar, except for that in aorta, which was 3 times greater. Phenylephrine (alpha-1 adrenoceptor selective agonist) or norepinephrine (nonselective adrenoceptor agonist) produced similar maximal responses in all vessels. The alpha-2 adrenoceptor selective agonist, B-HT 920 (2-amino-6-allyl-3,4,7,8-tetrahydro-6H-thiazolo[5,4-d]-azepine)-induced contraction in veins but not in arteries. Prazosin (10(-6) M) inhibited completely the contractions to norepinephrine (3 x 10(-6) M) in mesenteric arteries and to phenylephrine (3 x 10(-6) M) in arteries and veins. Contractile responses of mesenteric artery were unaffected by rauwolscine. Rauwolscine (10(-7) M) caused a greater parallel rightward shift of the concentration-response curve to norepinephrine than did prazosin (10(-7) M) in saphenous veins, and a further rightward shift of responses to norepinephrine after 10(-7) M prazosin in mesenteric vein and saphenous vein and abolished B-HT 920-induced responses at alpha-2 adrenoceptors. The tissues responding to B-HT-920 correspond to those having the highest alpha-2 receptor density as measured by [3H]rauwolscine binding. The density of such sites required for contraction to be initiated in veins was much higher than with alpha-1 adrenoceptor sites.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550616

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice.

Authors:  Chihiro Hosoda; Akito Tanoue; Mari Shibano; Yoshio Tanaka; Masami Hiroyama; Taka-aki Koshimizu; Susanna Cotecchia; Tadaichi Kitamura; Gozoh Tsujimoto; Katsuo Koike
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

2.  Alloxan inhibits ligand binding to adrenoceptors of vascular smooth muscle microsomes.

Authors:  C Y Kwan; S Sipos; V Gaspar
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

3.  Alpha-adrenoceptor subtypes in dog saphenous vein that mediate contraction and inositol phosphate production.

Authors:  P E Hicks; M Barras; G Herman; P Mauduit; J M Armstrong; B Rossignol
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

4.  The relationship between density of alpha-adrenoceptor binding sites and contractile responses in several porcine isolated blood vessels.

Authors:  I K Wright; N A Blaylock; D A Kendall; V G Wilson
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

5.  Interactions of chloroethylclonidine with rauwolscine- and prazosin-sensitive adrenoceptors in dog saphenous vein.

Authors:  A M Low; D M Bowdish; T R Prashad; V Gaspar
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

6.  Unusual alpha-adrenoceptor subtype in canine saphenous vein: comparison to mesenteric vein.

Authors:  E E Daniel; A M Low; V Gaspar; H Lu-Chao; J Green; J Akrong; S Duerksen; C Soyka; C K Chen; J Boyd; C Y Kwan
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.